Jupiter Neurosciences Collaborates with Zina Biopharmaceuticals to Advance Jotrol in P-II Trial for Parkinson’s Disease
Shots:
- Jupiter has partnered with Zina to support its P-IIa trial of Jotrol for assessing its safety & tolerability (1EP), and PK/PD (2EP) in Parkinson’s pts
- As per the agreement, Zina will provide services for P-IIa trial such as protocol design assistance (PK, biomarkers), regulatory strategy, & trial site selection
- Jotrol (micellar formulation) enhances resveratrol's bioavailability while reducing GI side effects. Preclinical studies show its potential in targeting neurodegeneration biomarkers, supporting its potential for Parkinson’s & other CNS disorders
Ref: Globenewswire | Image: Jupiter Neurosciences
Related News:- Siolta Therapeutics Enters into a Joint Research Agreement with Cowellnex
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
